Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Alcidion Group has signed a three-year deal with Australian private healthcare provider Healthscope for $895,000
  • The three-year deal will see the companies work together to support Healthscope’s vision for using data to drive transformation
  • Alcidion will develop dashboards to support predictive analytics and long-range planning

Alcidion Group has signed a three-year deal with Australian private healthcare provider Healthscope for $895,000.

Healthscope is a leading private healthcare provider with 43 private hospitals in Australia and New Zealand. It has a team of 18,000 people and 17,500 accredited medical practitioners.

Alcidion aims to transform healthcare with smart and initiative technology solutions that meet the needs of hospital and allied healthcare worldwide.

The company offers a complementary set of software products and services that create a unique offering in the global healthcare market.

The three-year deal will see the companies work together to support Healthscope’s vision for using data to drive transformation in the way healthcare is managed and delivered.

Using data from Healthscope’s hospitals, Alcidion will develop dashboards to support predictive analytics and long-range planning for Healthscope services.

Alcidion Managing Director Kate Quirke is excited to establish a relationship with Healthscope to increase the data and analytic capabilities across the organisation.

“This is Alcidion’s first implementation of our data analytics capabilities into a private hospital group. It demonstrates how important data is becoming across the healthcare sector,” she said.

Alcidion technology is implemented in over 215 hospitals across Australia, the U.K. and New Zealand and is currently working with over 42 healthcare organisations.

“We look forward to sharing our extensive capabilities around health care data management to assist Healthscope to drive better outcomes,” Kate added.

Alcidion Group has gained 13.1 per cent on the ASX today and is currently selling shares for 23 cents apiece at 12:58 pm AEST.

ALC by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.